AstraZeneca could spin off China business
FT News Briefing
00:00
Exploring AstraZeneca's Potential Spin-Off of China Business
This chapter examines AstraZeneca's potential spin-off of its China business in light of US-China tensions. It highlights the broader implications for the pharmaceutical industry in China, focusing on the lucrative market opportunities presented by an aging population and rising chronic diseases.
Play episode from 01:43
Transcript
